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Summary We have investigated whether an alternating induction chemotherapy regimen of PVB BEP is
superior to BEP in patients with poor-prognosis testicular non-seminoma. A total of 234 eligible patients were
randomised to receive an alternating schedule of PVB/BEP for a total of four cycles or four cycles of BEP.
Poor prognosis was defined as any of the following: lymph node metastases larger than 5 cm, lung metastases
more than four in number or larger than 2 cm, haematogenic spread outside the lungs, such as in liver and
bone, human chorionic gonadotrophin> 10 000 IU I -' or alphafetoprotein> 1000 IU 1-'. The complete
response (CR) rates to PVB/BEP and BEP were similar, 76% and 72% respectively (P = 0.58). In addition,
there was no significant difference in relapse rate, disease-free and overall survival at an average follow-up of 6
years. The 5-year progression-free and survival rates in both treatment groups were approximatley 80%. The
PVBIBEP regime was more toxic with regard to bone marrow function; the frequencies of leucocytes below
1000 gIl-', leucocytopenic fever and platelets below 25000 gi1', throughout four cycles were 28% vs 5%
(P<0.001), 16% vs 5% (P= 0.006), and 10% vs 1% (P= 0.001) respectively. Neuropathy also occurred more
often in the PVB,BEP arm: 47% vs 25% (P=0.001). This study shows that an alternating regimen of
PVB'BEP is not superior to BEP and that it is more myelo- and neurotoxic.
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Cisplatin combination chemotherapy has increased the long-
term survival rates of patients with disseminated testicular
non-seminoma from 10% to approximately 70% (Einhorn,
1981; Stoter et al., 1989). Variables associated with a poor
prognosis include extent of metastases and serum levels of
a-subunit of human chorionic gonadotrophin (HCG) above
10000 IU 1-' and/or alphafetoprotein (AFP) above 1000
IU 1-1 (Medical Research Council, 1985; Bosl et al., 1983;
Birch et al., 1986; Stoter et al., 1987). Several studies have
shown that complete (CR) rates fall by 30-50% in the
presence of one or more poor-prognosis factors (Bajorin et
al., 1988; Mead et al., 1992).
Etoposide has been shown to be active against cisplatin-
resistant germ cell tumours, indicating non-cross-resistance
(Williams et al., 1980; Bosl et al., 1985). Moreover, the
combination of cisplatin, etoposide and bleomycin (BEP) has
greater anti-tumour activity in poor-prognosis patients than
the combination of cisplatin, vinblastine and bleomycin
(PVB) (Williams et al., 1987). To improve the results of
induction chemotherapy in patients with poor-prognosis
criteria, both the introduction of new active agents and the
concept of alternating chemotherapy combinations could be
exploited (Goldie et al., 1982; Goldie and Coldman, 1984).
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Therefore, the Genitourinary Group of the European
Organization for Research and Treatment of Cancer
(EORTC) decided to perform a randomised study of four
cycles of induction chemotherapy comparing BEP as the
standard regimen with alternating cycles of PVB and BEP in
poor-prognosis patients. The definition of poor prognosis
was derived from the preceding EORTC study in which
PBV-treated patients with lymph node metastases > 5 cm or
lung metastases >2 cm achieved a CR rate of only 56% as
compared with 88% in patients with less extensive metastases
(Stoter et al., 1986).
Materials and methods
Patients were eligible for the study if they had metastatic
testicular non-seminoma with any of the following charac-
teristics: lymph node metastases > 5 cm, lung metastases
>4 in number or >2 cm, haematogenic spread outside the
lungs such as in liver or bone, HCG> 10 000 IU 1-' or AFP
> 1000 IU 1-'. These cut-off levels of serum markers were
based on prognostic factors analyses of EORTC (Stoter et
al., 1986) and MRC (Medical Research Council, 1985).
Patients were not accepted for the study if they had pure
seminoma in the primary tumour, brain metastases, prior
radiotherapy or chemotherapy, white blood count (WBC)
below 2000i1-', platelet count below 100000;lt-' or a
creatinine clearance below 44) mlmin-'.
Patients were randomised to receive four cycles of BEP or
alternating treatment cycles with PVB/BEP/PVB/BEP. BEP
consisted of cisplatin 20 mg m2 intravenously (i.v.) on days
1-5 every 3 weeks; etoposide, 120 mgm i.v. on days 1,3
and 5 every 3 weeks; and bleomycin 30mg i.v. on day 2,
weekly for 12 weeks. For PVB the schedule was the same as
for cisplatin and bleomycin, with vinblastine 0.15 mg kg-'
i.v. on days 1 and 2 every 3 weeks. If at the start of aBEP vsPB/ np -S-
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treatment cycle the WBC was below 1500pl-' or platelets
below 50 000yl 1, treatment was delayed for 1 week. If after
1 week the WBC was not above 3000 d-' and platelets
above 100000 l'-', dose modifications of etoposide and
vinblastine were applied. Cisplatin and bleomycin were with-
held if creatinine clearance fell below 40 mlmin-'. If renal
function recovered, cisplatin and bleomycin were resumed at
75% and 100% respectively. Severe skin toxicity and signs of
lung toxicity were reasons for termination of bleomycin.
After four cycles, patients with normal levels of tumour
markers and no clinical or roentgenographic evidence of
residual masses were classified as complete responders and
were followed without further therapy. Patients in whom
markers were normalised but who showed evidence of
residual tumour mass underwent debulking surgery. They
were classified as complete responders if histological
examination showed no viable cancer cells. Patients who still
had elevated tumour markers after four cycles and those with
viable cancer in the resected specimens were classified as
treatment failures.
Rising tumour markers or an increase in tumour volume
was considered as an endpoint indicating progression of
disease. Response rates to the treatment regimens were com-
pared by using the standard chi-square test for contingency
tables. For comparison oftoxicity, a chi-square test for linear
trend was used. Time to progression and duration of survival
curves were computed using the Kaplan-Meier product limit
method and were compared using the log-rani test (Breslow,
1984). The percentage of patients for whom follow-up was
available after 5 years was decreased owing to the policy of
several institutions to dismiss patients after 5 years. Informed
consent was obtained from all patients.
Results
Between March 1983 and August 1987, 250 patients were
entered, of whom 125 were randomised to BEP and 125 to
PVB/BEP. Sixteen patients (seven on BEP and nine on PVB/
BEP) were ineligible, predominantly because of histology
other than non-seminoma. Out ofthe 234 eligible patients, 26
(13 on each treatment) were not evaluable for response,
predominantly as a result of omitted explorative surgery.
However, all 234 eligible patients were included in the time to
progression and the survival analysis. Two patients on the
BEP arm died of malignant disease before the completion of
chemotherapy. On the PVB/BEP arm two patients died of
treatment related toxicity. These four patients were con-
sidered treatment failures.
Patient characteristics
Patient characteristics in the 234 eligible patients were well
balanced between the two treatment groups, except that
trophoblastic tumour elements were diagnosed in 20% of the
primaries in the patients on BEP compared with 13% on the
PVB/BEP arm. Sixty-five per cent of patients had retro-
peritoneal lymph node metastases >5 cm, 18% had media-
stinal and 16% had supraclavicular metastases. Forty- five
percent of the patients had >4 lung metastases and 31%
had lung metastases >2 cm. Liver and bone metastases were
present in 6% and 1% of the patients respectively.
According to currently accepted poor prognosis criteria
(Birch et al., 1986; Stoter et al., 1990; Mead et al., 1992),
17% of patients had abdominal masses >10cm and 14%
had 20 or more lung metastases. Nine percent of patients
had an HCG > 10000 IU I' and 23% had an AFP > 1000
Iu 1-'.
Response to treatment
A total of 105 patients on BEP and 103 patients on PVB/
BEP were evaluable for response. The CR were similar: 72%
and 76%, respectively (P = 0.58) (Table I). When the
inevaluable patients are included in the response analysis as
treatment failures, the CR rates were again not statistically
different 64% on BEP and 67% on PVB/BEP (P = 0.65).
After an average follow-up of 6 years (maximum 10 years)
the relapse rates from CR were 16% on BEP and 12% on
PVB/BEP (P = 0.50).
Time to progression andsurvival
There were no significant differences in time to progression
(P = 0.27) or duration of survival (P = 0.32) between the
treatment groups. Figure 1 gives the duration of survival by
treatment group for all 234 eligible patients. The 5 year
progression-free and survival rates in both treatment groups
are approximately 80%. When the log-rank survival analysis
is restricted to the group of complete responders, the 5 year
survival is 92%. Nine complete responders have died on BEP
and six on PVB/BEP, thus there is again no significant
difference between the two groups (P = 0.41).
Surgery
A total of 138 (67%) of the 204 fully evaluable patients
underwent explorative surgery to assess the response to treat-
ment. Twenty-four (17%) still had viable cancer cells, that is
14 (20%) of 71 patients on BEP and 10 (15%) of 67 patients
on PVB/BEP. In 61 patients (44%), the resected specimen
showed mature teratoma. The remaining 53 patients had
fibronecrotic remnants or normal architecture. Eight (33%)
of the patients with residual cancer and eight (13%) of the
patients with mature teratoma relapsed and died of cancer.
Toxicity
The haematological toxicity throughout four cycles in the 234
eligible patients is presented in Table II. The frequencies of
leucocytes below 1 000#I-' (28% vs 5%), leucocytopenic
fever (16% vs 5%) and platelets below 2500001lu (10% vs
1%) are all significantly higher on the PVB/BEP arm.
Table III presents the non-hematological toxicity. Nausea,
vomiting, paraesthesia, skin reactions and mucositis were the
most frequent side-effects. Neuropathy occurred significantly
more frequently in the PVB/BEP arm: 47% vs 25%
(P= 0.001). As a result of toxicity, chemotherapy dosages
were reduced in 60% of patients on PVB/BEP and in 68% of
Table I Response to treatment
BEP PVB/BEP p-vahe
Eligible 118 116
Inevaluable 13 13
Earlydeath 2 2
CR/eligible 76 (64%) 78 (67%) 0.65
CR/evaluable 76 (72%) 78 (76%) 0.58
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Table II Haematological toxicity
Side-effects BEP PVB BEP p-value
Leucocytes<l 0001j-l 6118 (5%) 32 116 (28%) <0001
(WHO grade 4)
Leucocytopenic fever 6 118 (5%) 19 116 (16%0) 0.006
(leucocytes < 2 000pl1
T> 38°C)
Platelets<25000s1t' 1 118 (1%) 12 116(10%) 0.001
(WHO grade 4)
Table III Non-haematological toxicity
BEP PVB BEP p-value
Renal (creatinine 3 118(3%) 3 116 (3%)
> 1.25 N)
Allergic reactions 6 118 (5%) 6 116 (5%)
Gastrointestinal 112 118 (97%) 114 116 (98%)
Neuropathy 29 118 (25%) 54 116 (47%) <0.001
Mucosal 19 118 (16%) 32 116(28%) <0.05
Skin 56 118 (47%) 50 116 (43%)
Pulmonary (fibrosis) 4 118 (3%) 3 116 (3%)
patients on BEP. Chemotherapy was postponed in 24% of
patients on PVB PEB and in 20% of patients on BEP.
The rationale for alternating administration of different
chemotherapy combinations is based on the assumption that
a tumour contains cell populations that are sensitive to one
drug but resistant to another agent. Such heterogeneity may
either exist at the initiation ofcytostatic treatment or develop
during treatment as a result of biochemical modulation or
genetic mutation (Goldie et al., 1982; Goldie and Coldman,
1984). In the case of germ cell cancer it is likely that natural
resistance is involved since these tumours proliferate rapidly
and the duration of induction chemotherapy is restricted to 3
or 4 months. These considerations favour the approach with
alternating chemotherapy as the initial treatment in patients
with poor-prognosis germ cell tumours.
This randomised study comparing four cycles of BEP with
an alternating regimen of PVB,'BEP for a total of four cycles
in poor-prognosis patients shows no differences in CR rates,
time -to progression and survival. PVB/BEP proved to be
considerably more toxic with regard to bone marrow sup-
pression, leucocytopenic fever and neuromuscular symptoms.
It is concluded that the alternating regimen of PVB/BEP
does not yield better treatment results than BEP, but is
accompanied by more toxicity. This is in agreement with the
results of a phase II study of EP VAB-6 at Memonral Sloan
Kettenrng Cancer Center, which yielded a relapse-free sur-
vival rate of 37% in a group of patients for whom a relapse-
free survival rate <50% was predicted (Bosl et al., 1987),
but is in contrast to the results of two single-institution phase
II studies including the POMB ACE regimen at the Charing
Cross Hospital (Cullen et al.. 1988; Hitchins et al., 1989) and
the CISCAVB schedule at the M.D. Anderson Hospital
(Logothetis et al., 1986), with which survival rates of 70-85%
have been achieved in poor-prognosis patients, defined as
bulky abdominal, mediastinal or pulmonary disease, or the
presence of liver, bone or brain metastases. It is difficult to
judge the relative merits of these alternating regimens as the
studies were not randomised and different prognostic selec-
tion criteria were used. The study here reported is the first
testicular cancer trial which investigated the concept of alter-
nating chemotherapy in a randomised fashion. Of note, the
standard arm in this study comprised BEP rather than PVB
to avoid the possibility that an eventual treatment advantage
of PVB, BEP could be due to the addition of etoposide
(Williams et al., 1987; Ozols et al., 1988). The explanation for
a lack of benefit of PVB/BEP over BEP may be mainly that
cisplatin resistance is the crucial factor for treatment failure
in testicular cancer. Since vinblastine and etoposide are not
cross-resistant, the alternation of these drugs may not be an
adequate method to test the concept of cross-resistance (Pas-
tan and Gottesman, 1987). Other agents with significant
activity in refractory disease such as ifosfamide (Loehrer et
al., 1989, 1993; Motzer et al.. 1992), and in particular the
taxanes (Hutter et al., 1994), are new candidates for alter-
nating drug combinations which may menrt further testing. In
addition to the testing of alternating chemotherapy, short
intervals between courses may also be further investigated.
Data from the Royal Marsden Hospital suggest that the dose
intensity of cisplatin at the beginning of the treatment may
be important (Horwich et al., 1989). The design of BOP/BEP
involved four cycles of bleomycin, vincristine and cisplatin
given over the initial 4 weeks, followed by three courses of
BEP at conventional 3 week intervals, yielding an 85% per-
sistingly disease-free survival rate in patients with poor-
prognosis disease. defined by large volume disease and or
liver. bone or brain metastasis. This study was followed by
the testing of three BOP cycles, followed by three VIP cycles
(Lewis et al., 1991), and this design has recently been inves-
tigaged in a randomised prospective MRC EORTC col-
laborative trial comparing BOP VIP with the 'gold standard
therapy' using BEP. The results of this trial are awaited.
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